

# **AREV Nutrition Sciences Inc.**

**MANAGEMENT DISCUSSION AND ANALYSIS  
OF THE FINANCIAL POSITION AND RESULTS OF OPERATIONS  
FOR THE YEAR ENDED 31 DECEMBER 2017**

Stated in Canadian Funds

Dated: 30 April 2018

**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

## **TO OUR SHAREHOLDERS**

This Management Discussion and Analysis (“MD&A”) supplements, but does not form part of the Financial Statements for the year ended 31 December 2017. Consequently, the following discussion and analysis of the financial condition and results of operations for AREV Nutrition Sciences Inc. (“AREV” or, the “Company”), should be read in conjunction with the audited Financial Statements for the year ended 31 December 2017 which have been prepared in accordance with International Financial Reporting Standards (“IFRS”), consistently applied.

Discussion of the Company, its operations and associated risks are further described in the Company’s filings, available for viewing at [www.sedar.com](http://www.sedar.com). A copy of this MD&A will be provided to any applicant upon request.

## **FORWARD-LOOKING STATEMENTS**

Certain statements contained in the following MD&A and elsewhere constitute forward-looking statements. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made, and readers are advised to consider such forward-looking statements in light of the risks set forth in the Company’s filings and herein. Additional information regarding the Company, including copies of the Company’s continuous disclosure materials is available through the SEDAR website at [www.sedar.com](http://www.sedar.com).

## **BUSINESS OVERVIEW**

AREV was incorporated under the Business Corporations Act (Alberta) on 22 November 2005. The Company owns an innovative line of emulsified 100% coconut derived MCT oil combined with Whey Protein to serve as base ingredients. The product line trademarked as COCO-MULSION will be sold online and distributed through Natural Health and Sport Nutrition stores. The COCO-MULSION products have been registered with Health Canada and target specific health benefits. The first two products released for distribution in February 2017 were the COCO-MULSION Original (providing a boost of energy and antioxidants) and COCO-MULSION Brain (improving cognitive behaviour).

The Company is listed on the Canadian Securities Exchange (“CSE”) under the symbol “AREV” (formerly “GNS”). The registered address of the Company is Suite 440, 890 West Pender Street, Vancouver, BC, V6C 1J9. The principal place of business of the Company is Unit 2, 9049 Shaughnessy Street, Vancouver, BC, V6P 6R9.

**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

**SIGNIFICANT EVENTS AND TRANSACTIONS DURING THE PERIOD**

On 23 January 2017, the Company announced the recent acquisition of one of the most sophisticated and advanced Fast Freeze Extraction (FFE) technologies currently on the market. Operating at lower temperatures, the extraction process preserves vital ingredients while yielding extracts of superior quality with no undesirable by-products. This FFE system can be used on many different biomass types and operates using non-hydrocarbon gas or solvents, including Cannabis in accordance with Health Canada.

On 13 March 2017, AREV is pleased to announce the launch of its web site [www.arenutrition.com](http://www.arenutrition.com) and the launch of its innovation COCO-MULSION product line at Natural Products Expo West in Anaheim, California where the company commenced its action plan to become the leader of nutraceutical products that are a hybrid of vitamin supplements and functional food, providing good daily nutrition for health conscious consumers.

On 20 April 2017, the Company's \$115,000 convertible debenture was converted into 2,300,000 units of the Company at \$0.05 per unit, with each unit consisting of one common share and one share purchase warrant of the Company.

On 23 May 2017, the Company entered into a credit facility agreement with a director of the Company, up to a maximum of \$50,000, to fund its operations. The credit facility is unsecured, bears interest at 10% per annum, compounded monthly, and is due on demand after 4 January 2018.

On 6 September 2017, the Company announced that it has arranged a private placement for up to 4,000,000 units at a price of \$0.25 per Unit for gross proceeds of \$1,000,000. Each Unit is comprised of one common share of the Company and one-half of one common share purchase warrant (each whole one, the "Warrants") and each Warrant being exercisable at \$0.40 per Warrant Share. Subject to adjustment in certain events, each whole Warrant entitles the holder thereof to purchase one additional common share of the Company at any time on or before the date that is 18 months from the date of issuance of the Warrants; except that, if over a period of 10 consecutive trading days between the date that is 4 months and a day from the date of issuance of the Warrants and the date that the Warrants would otherwise expire, the closing price of the Company's common shares exceeds \$0.60, then the Company may, at its option, provide written notice to the warrant holders to exercise their Warrants within 30 days of the date of the notice, failing which the warrants will expire.

On 8 September 2017, the Company announced that Long Trinh, CPA, CA has joined the team as Chief Financial Officer.

On 8 September 2017, the Company issued 600,000 common shares as a signing bonus to consultants of the Company.

On 18 September 2017, the Company announced that Guy Dancosse has joined the team as a director, effective September 18, 2017. The Company granted 100,000 stock options as a signing bonus, and put in place a milestone bonus of 200,000 common shares of the Company for signing a definitive agreement with strategic alliances that are currently under discussion.

On 31 October 2017, the Company announced that it has entered into two letters of intent to acquire 100% of the issued and outstanding shares of Verified Plant Genetics and a property in Parksville, BC.

On 13 November 2017, the Company reports that the private placement announced on 6 September 2017 has been oversubscribed. The Company now proposes to issue 5,000,000 units at a price of \$0.25 per Unit, for gross proceeds of up to \$1,250,000.

**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

**EVENTS SUBSEQUENT TO 31 DECEMBER 2017.**

On 8 January 2018, a company controlled by a director of the Company converted a \$300,000 convertible debenture into 6,000,000 Units of the Company. Each Unit consists of one common share and one common share warrant. After converting the debenture, the private company exercised 2,000,000 warrants at a price of \$0.05 per warrant.

On 17 January 2018, the Company announced a binding agreement (the Acquisition Agreement”) to acquire 100% of the issued and outstanding shares of We Grow BC Ltd. (“WGBC”). WGBC is a private company located in British Columbia and holds a Cultivation License pursuant to the Access for Cannabis Medical Purposes Regulations under Health Canada. The Company’s intention is to enter into an amalgamation by plan of arrangement where the amalgamation shall take place between a wholly owned subsidiary of AREV and WGBC. The acquisition agreement provides for each shareholder of WGBC to receive 90,909 shares of AREV in exchange for each share of WGBC based on a \$50,000,000 valuation of WGBC. It is anticipated that a total of 100,000,000 AREV shares will be issued at a deemed price of \$0.50 per share. AREV’s intention is to enter into an amalgamation by plan of arrangement where the amalgamation shall take place between a wholly owned subsidiary of AREV and WGBC.

On 8 February 2018, the Company announced the appointment of Derek Sider as CFO, and the resignation of Long Trinh as CFO.

On 8 February 2018, the Company issued 405,000 stock options to officers and consultants of the Company at a price of \$0.56 per option for a period of five years from the date of issuance. 25,000 of these options will vest immediately, and the remaining 380,000 options will vest on a two year vesting schedule: one third immediately, one third at the one year mark, and one third at the second year mark.

Subsequent to year-end, the Company issued 1,700,000 common shares in connection with the exercise of warrants.

**RESULTS OF OPERATIONS**

The Company incurred a net loss of \$1,019,941 during the year ended 31 December 2017, compared with a net loss of \$251,658 in the comparative period. The main fluctuations in cost are as follows:

Share-based payments (rounded to the nearest ‘000)	12 months 2017	12 months 2016
	\$ 197,000	\$ 35,000
Variance increase	\$ 162,000	

The recognition of share-based payment expense results from the timing of granting of equity-based awards. During the year ended 31 December 2017, the Company granted 600,000 common shares and 200,000 options to directors, officers, employees and consultants of the Company. 700,000 common shares with a fair value of \$35,000 were granted to the CEO and a director of the Company as signing bonuses during the year ended December 31, 2016.

Management fees (rounded to the nearest ‘000)	12 months 2017	12 months 2016
	\$ 163,000	\$ 48,000
Variance increase	\$ 115,000	

**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

In connection with an increase in operations during the fourth quarter of fiscal 2016, the Company's management began charging management fees. Management fees incurred during the year ended 31 December 2017 are expected to continue in fiscal 2018.

Consulting fees (rounded to the nearest '000)	12 months 2017	12 months 2016
	\$ 111,000	\$ 22,000
Variance increase	\$ 89,000	

The increase in advertising expense results from preparation for a new product line with coconut flavour that was introduced on 15 December 2016 launched in early 2017.

Amortization and depreciation (rounded to the nearest '000)	12 months 2017	12 months 2016
	\$ 52,000	\$ 7,000
Variance increase	\$ 45,000	

The increase in amortization and depreciation results from the acquisition of equipment during the third quarter of fiscal 2016 and is consistent with the expectations of management.

Interest expense (rounded to the nearest '000)	12 months 2017	12 months 2016
	\$ 37,000	\$ 18,000
Variance increase	\$ 19,000	

The increase in interest expense results primarily from the issuance of convertible debentures and loans payable bearing simple interest at a rate of 10% per annum, as well as the accretion of the convertible feature of the convertible debentures.

### SELECTED ANNUAL INFORMATION

The following table summarizes selected financial data for the Company for each of the four most recently completed financial years. The information set forth below should be read in conjunction with the consolidated audited financial statements, prepared in accordance with International Financial Reporting Standards and Canadian generally accepted accounting principles as applicable.

Fiscal Year Ended	IFRS Dec-17	IFRS Dec-16	IFRS Dec-15	IFRS Dec-14
Total revenues	-	-	-	-
Loss and comprehensive loss for the year	(1,019,941)	(251,658)	(84,156)	(75,223)
Loss per share (basic and diluted)	(0.07)	(0.12)	(0.00)	(0.00)
Total assets	1,658,827	794,038	17,339	3,503
Total liabilities	699,570	610,283	181,676	83,684
Cash Dividends declared	-	-	-	-

**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

**SUMMARY OF QUARTERLY RESULTS**

The following table sets out selected unaudited quarterly financial information of the Company and is derived from the unaudited condensed interim financial statements prepared by management. The Company's interim financial statements are prepared in accordance with International Financial Reporting Standards and are expressed in Canadian dollars.

Three months ended	Dec-17	Sep-17	Jun-17	Mar-17	Dec-16	Sep-16	Jun-16	Mar-16
	\$	\$	\$	\$	\$	\$	\$	\$
Total revenue	-	-	-	-	-	-	-	-
Comprehensive loss	(422,050)	(308,187)	(159,787)	(129,917)	(108,063)	(63,836)	(42,563)	(37,196)
Loss per share	(0.02)	(0.02)	(0.01)	(0.01)	(0.01)	(0.06)	(0.04)	(0.04)
Total assets	1,658,827	582,908	583,291	647,554	794,038	572,575	17,960	15,942
Working capital (deficit)	776,734	(370,308)	(251,049)	(111,381)	(3,079)	(451,799)	(252,324)	(210,029)

- The increased loss during the period ended December 31, 2016 resulted from interest and accrued expense incurred on convertible debentures issued in September 2016, as well as the issuance of 700,000 common shares with a fair value of \$35,000 granted to officers and directors of the Company.
- The increased loss during the period ended 30 September 2017 resulted from the issuance of 600,000 common shares of the Company with a fair value of \$150,000 as signing bonuses to consultants.
- The increased loss during the period ended 31 December 2017 resulted from the granting of share based awards to officers, directors, and consultants of the Company, as well as the impairment of intangible assets in the amount of \$144,441.
- The increase in working capital during as at 31 December 2017 resulted from financing activities which raised an aggregate of \$1,425,600 during the year ended 31 December 2017 compared to \$308,216 during the year ended 31 December 2016.

**ADDITIONAL DISCLOSURE FOR VENTURE ISSUERS WITHOUT SIGNIFICANT REVENUE**

An analysis of material components of the Company's general and administrative expenses is disclosed in the annual audited financial statements for the year ended December 2017 to which this MD&A relates.

**OUTSTANDING SHARE DATA**

- As at 30 April 2018, the Company had 32,684,200 common shares issued and outstanding.
- As at 30 April 2018, the Company had 9,264,600 share purchase warrants outstanding.
- As at 30 April 2018, the Company had 605,000 stock options outstanding.

**FINANCIAL POSITION AND LIQUIDITY**

The Company does not have sufficient working capital to continue operations in the normal course for the foreseeable future and will require additional financing to remain financially solvent.

**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

The Company's financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at 31 December 2017, the Company has not generated any revenues from operations, has a working capital surplus of \$776,734, and has an accumulated deficit of \$2,605,953. The Company's ability to continue as a going concern is dependent upon its ability to generate and maintain future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management is of the opinion that sufficient working capital will be obtained from external financing to meet the Company's liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These factors indicate the existence of a material uncertainty that may cast doubt on the ability of the Company to continue as a going concern.

As at 31 December 2017, the Company's financial instruments consist of cash, amounts receivable, accounts payable and accrued liabilities, amounts due to related parties, and convertible debentures. The Company has no speculative financial instruments, derivatives, forward contracts or hedges.

The following discussion relates to the year to date period and compares that to the same period in fiscal 2016.

Cash used in operating activities during the year ended 31 December 2017 totalled \$448,130 (comparative period: \$111,248). This is consistent with the expectations of management.

Cash used in investing activities during the year ended 31 December 2017 totalled \$113,029 (comparative period: \$4,552).

As a result of the utilization of the Company's credit facility and the closing of a private placement, cash raised in financing activities during the year ended 31 December 2017 totalled \$1,425,600 (comparative period: \$308,216).

Management is currently investigating a range of strategic options available with a view to generating income sufficient to pay its liabilities and ongoing operating expenses, and maximizing shareholder value. The Company may be required to obtain additional debt or equity financing or curtail spending in the future to fund operations and settle obligations.

### **OFF-BALANCE SHEET ARRANGEMENTS**

The Company does not have any off-balance sheet arrangements for the year ended 31 December 2017.

### **PROPOSED TRANSACTIONS**

The Company does not currently have any proposed transactions approved by the Board of Directors.

**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

**RELATED PARTY TRANSACTIONS**

Transactions and balances with related parties not disclosed elsewhere in the Financial Statements are as follows:

**RELATED PARTY DISCLOSURE**

<b>Name and Principal Position</b>	<b>Period<sup>(i)</sup></b>	<b>Remuneration or fees<sup>(ii)</sup></b>	<b>Share-based awards</b>	<b>Amounts Payable</b>
The Chief Executive Officer of the Company	2017	\$ 102,600	-	4,135
	2016	\$ 27,733	25,000	4,135
The former Chief Financial Officer of the Company	2017	\$ 19,167	87,500	14,167
	2016	\$ -	-	-
A director of the Company	2017	\$ -	15,000	-
	2016	\$ -	-	-
A director of the Company	2017	\$ -	-	-
	2016	\$ 2,000	10,000	-
A director of the Company	2017	\$ -	-	49,533
	2016	\$ 18,000	31,826	43,499

<sup>(i)</sup> For the years ended 31 December 2017 and 31 December 2016

<sup>(ii)</sup> Amounts disclosed were paid or accrued to the related party.

On 8 July 2015, the Company entered into an agreement with a director of the Company to advance funds to the Company for a maximum amount of \$100,000 to cover operating costs. The loan was unsecured, bore interest at 10% per annum, compounded monthly, and was due on demand. During the year ended 31 December 2015, \$51,805 was advanced to the Company. During the year ended 31 December 2016, a further \$41,543 was advanced to the Company. On 15 September 2016, the Company entered into an agreement with this director to convert \$93,348 in principal, \$7,319 in accrued interest, and \$14,333 in accounts payable owed to this director into a convertible debenture with a principal balance of \$115,000. This note was converted on 20 April 2017. See Note 14.

Included in accounts payable as at 31 December 2017 is \$116,975 (2016 - \$nil) owing a company with directors in common for the purchase of fast freeze extraction equipment (see Note 8).

These transactions were in the normal course of operations, which is the amount of consideration established and agreed to by the related parties.

**COMMITMENTS**

The Company has a licencing and royalty memorandum of understanding with the initial developer of the technology that is being utilized exclusively by the Company for the production of products from ginseng roots. As part of the memorandum of understanding, the Company is required to pay a royalty of 5% of the invoiced cost of each production run incurred by the Company.

On 16 September 2016, the Company entered into an agreement with the CEO of the Company whereby the Company agreed to pay \$8,000 per month for services rendered. The Company also paid the CEO of the Company a one-time signing bonus of \$25,000 by issuance of 500,000 common shares upon signing of the agreement. The Company is to pay a one-time bonus of \$100,000 payable by the issuance of 1,000,000 common shares of the Company, immediately following public filing of annual financial statements of the Company which show revenue in excess of \$1,000,000 in the completed fiscal year.



**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

On 27 August 2015, the Company entered into a premises lease agreement that started on 1 September 2015 and ends on 31 August 2018 with a two year option to extend. Expected annual payments under this lease arrangement are as follows:

2018	\$	22,046
<b>Total</b>	<b>\$</b>	<b>22,046</b>

### **RISKS AND UNCERTAINTIES**

The Company is in the biotechnology business focusing on nutraceutical products and as such is exposed to a number of risks and uncertainties that are not uncommon to other companies in the same business. The Company has no ongoing revenue or income from operations. The Company has limited capital resources and has to rely upon the sale its assets or sale of its common shares for cash required to make new investments and to fund the administration of the Company.

These risks may not be the only risks faced by the Company. Additional risks and uncertainties not presently known by the Company or which are presently considered immaterial may also adversely impact the Company's business, results of operations, and financial performance. The most significant risks and uncertainties faced by the Company are (in no specific order) are:

There is expressed doubt about our ability to continue as a going concern, which may hinder our ability to achieve our objectives

The Company's ability to realize the inherent value of its assets is dependent on successfully advancing its technologies to market through product development and ultimately achieving future profitable operations, the outcome of which cannot be predicted at this time, or in the alternative being able to sell the assets for proceeds equal to their carrying value or greater.

We have no committed sources of additional capital. In the future we may need to raise additional capital through equity financings. Additional equity financings could result in significant dilution to shareholders. Funds may not be available to us in the future on favourable terms, if at all, and we may be required to delay, reduce the scope of, or eliminate research and development efforts and the patent protection for our product candidates.

We have completed the development of two commercial products, but do not have any revenues from the sale of products; we may not achieve profitability.

We have completed the development of two commercial products, we have not begun to market or generate revenues from sales of the products we are developing. We do not anticipate that we will generate revenue from the sale of products in the foreseeable future.

There can be no assurance that any of our product candidates will meet applicable health regulatory standards, obtain required regulatory approvals, be capable of being produced in commercial quantities at reasonable costs, be successfully marketed or that the investment made in such product candidates will be recouped through sales or related royalties. There can be no assurance that we will ever achieve profitability. As a result, an investment in our common shares involves a high degree of risk and should be considered only by those persons who can afford a total loss of their investment.

Our products may not gain meaningful market acceptance, and we may not become profitable.

**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

We may not be able to contend successfully with competitors. The biotechnology industries are highly competitive and subject to significant and rapid technological change as researchers learn more about diseases and develop new technologies and treatments. Our current and potential competitors generally include major multinational pharmaceutical companies, biopharmaceutical firms, specialty pharmaceutical companies, universities and other research institutions.

Many of our competitors, either alone or together with their collaborators, have substantially greater financial resources and larger research, development and regulatory staffs than ours. There can be no assurance that competitors will not develop more effective or more affordable products or product commercialization than us and our corporate collaborators.

If our product candidates fail to gain market acceptance, we may be unable to earn sufficient revenue to continue our business. If our product does not become widely accepted, it is unlikely that we will ever become profitable.

Our product candidates subject us to the risk of product liability claims for which we may not be able to maintain or obtain adequate insurance coverage

Inherent in the use of our product, is the risk of financial exposure to product liability claims and adverse publicity in the event that the use of such products results in personal injury or death. There can be no assurance that we will not experience losses due to product liability claims in the future.

We may encounter difficulties in manufacturing our products delaying or preventing the development or commercialization of our product candidates

There can be no assurance that our product candidate can be manufactured at a cost or in quantities necessary to make them commercially competitive or even viable. We do not have any manufacturing facilities and we are dependent on third party contract manufacturers and/or collaborators to produce our product. There can be no assurance that such third party manufacturers or collaborators will be able to meet our needs with respect to timing, quantity, quality or pricing. If we are unable to contract for a sufficient supply of product on acceptable terms, or if we should encounter delays or difficulties in our relationships with manufacturers or collaborators, and/or product sales would be delayed, thereby delaying the submission of products for market introduction and subsequent sales of such products.

Our success depends on the management of growth

Our future growth, if any, may cause a significant strain on management, operational, financial and other resources. The failure of our management team to effectively manage growth could have a material adverse effect on our business, financial condition and results of operations.

Our success depends on our ability to protect our proprietary rights and operate without infringing the proprietary rights of others;

Our success will depend in part on our ability to obtain and enforce patents and maintain trade secrets.

Our commercial success depends significantly on our ability to operate without infringing the patents and proprietary rights of third parties, and there can be no assurance that our products do not or will not infringe on the proprietary rights of others.

**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

Litigation may also be necessary to enforce technology licensed to us or to determine the scope and validity of a third party's proprietary rights. We could incur substantial costs if litigation is required to defend ourselves in such suits.

Certain of the Company's directors and officers may, from time to time, serve in similar positions with other public companies, which may put them in a conflict position from time to time.

Certain of the Company's directors and officers may, from time to time, serve as directors or officers of other companies involved in similar businesses to the Company and, to the extent that such other companies may participate in the same ventures in which the Company may seek to participate, such directors and officers may have a conflict of interest in negotiating and concluding terms respecting the extent of such participation. Such conflicts of the Company's directors and officers may result in a material and adverse effect on the Company's results of operations and financial condition.

Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, then actual results may vary materially from those described in forward-looking statements.

**FINANCIAL INSTRUMENTS AND RISK MANAGEMENT**

**a) Fair Values**

Assets and liabilities measured at fair value on a recurring basis were presented on the Company's condensed interim statement of financial position as 31 December 2017 are as follows:

		Fair value measurements using			
		Quoted prices in active markets for financial instruments (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Carrying amount at 31 December 2017
<b>Cash</b>	<b>\$</b>	<b>1,058,578</b>	<b>\$</b>	<b>-</b>	<b>\$</b>
					<b>1,058,578</b>

The fair values of other financial instruments, which include amounts receivable, accounts payable and accrued liabilities, credit facility, and amounts due to related parties, approximate their carrying values due to the relatively short-term maturity of these instruments.

The initial fair value of the liability component of the Company's convertible debenture, with a carrying amount of \$284,675 as at 31 December 2017. The fair value for the liability component of convertible debenture was estimated using the discounted cash flows technique. The valuation model considers the present value of expected payments, discounted using a discount rate that approximates the market rate for the Company's loans and borrowings. The estimated fair value would increase (decrease) if the market rate of borrowing were lower (higher).

**b) Credit Risk**

Credit risk is the risk of financial loss to the Company if any counterparty fails to discharge its obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and amounts receivable. The Company limits its exposure to credit loss by placing its cash with high credit quality financial institutions. Amounts receivable consists primarily of GST receivable from the Government of Canada. The carrying amount of financial assets represents the maximum credit exposure.

**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

**c) Interest Rate Risk**

The Company's cash may contain highly liquid investments that earn interest at market rates. The Company manages its interest rate risk by maximizing the interest earned on excess funds while maintaining the liquidity necessary to fund daily operations. Fluctuations in market interest rates do not have a significant impact on the Company's results of operations due to the short term to maturity of the investments held.

**d) Liquidity Risk**

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company currently settles its financial obligations out of cash. The ability to do this relies on the Company raising debt or equity financing in a timely manner and by maintaining sufficient cash in excess of anticipated needs. Management closely monitors cash flow requirements to ensure that it has sufficient cash on demand to meet operational and financial obligations as they become due.

**CAPITAL MANAGEMENT**

The Company manages its capital to maintain its ability to continue as a going concern and to sustain future development of the business. The capital structure of the Company consists of cash and equity comprised of issued share capital, share subscriptions receivable, equity portion of convertible debentures, and share-based payment reserve.

The Company manages its capital structure and makes adjustments to it according to economic market conditions. Management monitors the Company's ongoing capital requirements against unrestricted net working capital and assesses expected capital requirements for the fiscal period. In order to maintain or adjust the capital structure, the Company may adjust spending, issue new shares, sell assets, or incur debt.

The Company is not subject to externally imposed capital requirements and there have been no changes to the Company's capital management policy during the year ended 31 December 2017.

**INVESTOR RELATIONS ACTIVITIES**

With respect to public relations, the Company's policy is to provide information from its corporate offices to investors and brokers directly.

**MANAGEMENT**

The Company is dependent upon the personal efforts and commitments of its existing management. To the extent that management's services would be unavailable for any reason, a disruption to the operations of the Company could result, and other persons would be required to manage and operate the Company.

**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

## **DISCLOSURE CONTROLS AND PROCEDURES**

Management is responsible for designing internal controls over financial reporting in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company's financial statements for external purposes in accordance with IFRS. The design of the Company's internal control over financial reporting was assessed as of the date of this MD&A.

Based on this assessment, it was determined that certain weaknesses existed in internal controls over financial reporting. As indicative of many small companies, the lack of segregation of duties and effective risk assessment were identified as areas where weaknesses existed. The existence of these weaknesses is to be compensated for by senior management monitoring. The officers will continue to monitor very closely all financial activities of the Company and increase the level of supervision in key areas. It is important to note that this issue would also require the Company to hire additional staff in order to provide greater segregation of duties. Since the increased costs of such hiring could threaten the Company's financial viability, management has chosen to disclose the potential risk in its filings and proceed with increased staffing only when the budgets and work load will enable the action. The Company has attempted to mitigate these weaknesses, through a combination of extensive and detailed review by management of the financial reports, the integrity and reputation of senior accounting personnel, and candid discussion of those risks with the audit committee.

## **FORWARD-LOOKING INFORMATION OR STATEMENTS AND CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS**

Certain statements contained in the following MD&A constitute forward-looking statements (within the meaning of the Canadian securities legislation and the U.S. Private Securities Litigation Reform Act of 1995) that involve risks and uncertainties. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible" and similar expressions, or statements that events, conditions or results "will", "may", "could" or "should" occur or be achieved. The forward-looking statements may include statements regarding work programs, capital expenditures, timelines, strategic plans, market price of commodities or other statements that are not statement of fact. Forward-looking statements are statements about the future and are inherently uncertain, and actual achievements of the Company may differ materially from those reflected in forward-looking statements due to a variety of risks, uncertainties and other factors. For the reasons set forth above, investors should not place undue reliance on forward-looking statements. Important factors that could cause actual results to differ materially from the Company's expectations include uncertainties involved in disputes and litigation, fluctuations in currency exchange rates; uncertainty of estimates of capital and operating costs; the need to obtain additional financing and uncertainty as to the availability and terms of future financing; and other risks and uncertainties disclosed in other information released by the Company from time to time and filed with the appropriate regulatory agencies.

It is the Company's policies that all forward-looking statements are based on the Company's beliefs and assumptions, which are, based on information available at the time these assumptions are made. The forward looking statements contained herein are as of 30 April 2018 and are subject to change after this date, and the Company assumes no obligation to publicly update or revise the statements to reflect new events or circumstances, except as may be required pursuant to applicable laws.

Although management believes that the expectations represented by such forward-looking information or statements are reasonable, there is significant risk that the forward-looking information or statements may not be achieved, and the underlying assumptions thereto will not prove to be accurate. Forward-looking information or

**AREV NUTRITION SCIENCES INC.**  
**FOR THE YEAR ENDED 31 DECEMBER 2017**  
Canadian Funds  
**MANAGEMENT DISCUSSION AND ANALYSIS**

statements in this MD&A include, but are not limited to, information or statements concerning our expectations regarding the ability to raise additional funds and find additional value in the biotechnology assets held.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking information or statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and factors including: the possibility that opportunities will arise that require more cash than the Company has or can reasonably obtain; dependence on key personnel; dependence on corporate collaborations; potential delays; uncertainties related to early stage of technology and product development; uncertainties as to fluctuation of the stock market; uncertainties as to future expense levels and the possibility of unanticipated costs or expenses or cost overruns; and other risks and uncertainties which may not be described herein. The Company has no policy for updating forward looking information beyond the procedures required under applicable securities laws.

**APPROVAL**

The Company's Board of Directors has approved the Company's financial statements for the year ended 31 December 2017. The Company's Board of Directors has also approved the disclosures contained in this MD&A. A copy of this MD&A will be provided to anyone who requests it and is available on [www.sedar.com](http://www.sedar.com).

Respectfully submitted on behalf of the Board of Directors,

**"Stephane Maher"**

Stephane Maher

Chief Executive Officer